A 6-month Venographic Follow-up in 164 Patients with Acute Deep Vein Thrombosis

Summary

A total of 164 patients were recruited from a randomized trial comparing a low molecular weight heparin, dalteparin, given subcutaneously once daily with a continuous intravenous infusion of unfractionated heparin in the initial treatment of acute deep vein thrombosis. The primary objective of this follow-up study was to investigate whether there were any differences between the two treatment groups with respect to Marder score changes 6 months after the initial diagnosis using repeated venography. The secondary objectives were to analyse whether certain haemostatic and acute phase parameters or patient characteristics influenced the venographic outcome. Results: Complete lysis of the thrombus was observed in 38.4% of the patients and a partial lysis in another 54.3% assessed by venography 6 months after the acute event. Extension of the thrombus was seen in 7.3% of the patients. There were no significant differences in the change in mean Marder score before treatment and at the 6 month follow-up between the two treatment groups, irrespective of thrombus localisation. In a regression model, male gender, low levels of orosomucoid and increased levels of d-di- mer in plasma on day 5 were independently associated (p <0.05) with an enhanced absolute resolution of the thrombus at 6 months. No differences in symptoms and signs in the thrombotic leg at follow-up, comparing the treatment given, or thrombus extension at diagnosis and 6 months later, were demonstrated. Conclusion: Dalteparin given once daily subcutaneously was as effective as continuous intravenous infusion of unfractionated heparin in the initial treatment of deep vein thrombosis assessed by Marder score evaluation 6 months after the acute event.

• References

• 1 Leizorovicz A, Simonneau G, Decousus A, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304
• 2 Lockner D. Low molecular weight heparin for treatment of established venous thromboembolism. In: Low molecular weight heparin in prophylaxis and therapy of thromboembolic disease. Bounameaux H. ed. Marcel Dekker Inc.; Basel: 1995: 283-305
• 3 ten CateJW, Koopman M, Prins M, Büller HR. Treatment of venous thromboembolism. Thromb Haemost 1995; 75 (01) 197-203
• 4 Holm HA, Ly B, Handeland GF, Abildgaard U, Amesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel B, Sortland O, Vinje B. Subcutaneous heparin treatment of deep venous thrombosis with low molecular weight heparin. Haemostasis 1986; 16 (Suppl. 02) 30-37
• 5 Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten CateJW. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
• 6 Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-190
• 7 Duroux P, Beclere A. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: A collaborative European multicentre study. Thromb Haemost 1991; 65: 251-256
• 8 Bratt G, Tomebohm E, Granquist S, Åberg W, Lockner D. A comparison between low molecular weight heparin (KABI2165) and standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-817
• 9 Bratt G, Åberg W, Johansson M, Tömebohm E, Granquist S, Lockner D. Two daily subcutaneous injections of Fragmin® compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-510
• 10 Common H, Seaman A, Rösch J, Porter J, Dotter C. Deep vein thrombosis treated with streptokinase or heparin. Angiology 1976; 27: 645-654
• 11 Elliot M, Immelman P, Jeffery P, Benatar R, Funston M, Smith B, Shepstone J, Ferguson D, Jacobs P, Walker W, Louw J. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 838-843
• 12 Isacsson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent idiopathic venous thrombosis. Acta Chir Scand 1972; 138: 313-319
• 13 Conard J, Veuillet-Duval A, Horellou MH, Samama M. Etude de la coagulation et de la fibrinolyse dans 131 cas de thromboses vineuses récidivantes. Nouvelle Revue Francaise d′Uématologie 1982; 24: 205-209
• 14 Schulman S, Wiman B. and the DURAC Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607-611
• 15 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
• 16 Marder VJ, Soulen RL, Atichartakam V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1118-1129
• 17 Marsh NA, Minter AJ, Chesterman CN. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Blood Coag and Fibrinolysis 1990; 1: 133-138
• 18 Grulich-Henn J, Preissner KT, Miiller-Berghaus G. Heparin stimulates fibrinolysis in mesothelial cells by selective induction of tissue-plasminogen activator but not plasminogen activator inhibitor-1 synthesis. Thromb Haemost 1990; 64: 420-425
• 19 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-485
• 20 Jansson J-H, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem 1989; 35: 1544-1545
• 21 The DVTenox study group. Markers of the hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost 1993; 70: 909-914